logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Stage II/III CRC: adding biologics to ACT yields poorer OS in meta-analysis

Bevacizumab an exception in the presence of microsatellite unstable tumors.